Newsroom
Truveta news releases
US health systems announce the Truveta Genome Project, creating the world’s largest and most diverse database to discover the science of humanity
The Regeneron Genetics Center® will sequence up to ten million exomes, helping to accelerate drug discovery and transform patient care BELLEVUE, Wash. – January 13, 2025 – Today, leading US health systems, including Advocate Health, CommonSpirit Health, Henry Ford...
Truveta achieves HITRUST r2 Certification, demonstrating the highest level of information protection assurance
HITRUST r2 Certification demonstrates Truveta’s relentless commitment to the highest standards of security and privacy to protect regulatory-grade data. BELLEVUE, Wash. – November 20, 2024 – Truveta announced that its platform Truveta Studio and Truveta Data have...
Truveta Data, the most complete, timely, and clean electronic health record data, now includes more than 120 million de-identified patients
Researchers with more than 100 organizations use regulatory-grade Truveta Data to enable their scientifically rigorous research BELLEVUE, Wash. – November 14, 2024 –Truveta announced today that Truveta Data, the most complete, timely, and clean electronic health...
Truveta Studio now includes Truveta Tru, a research assistant powered by generative AI
Trained on the Truveta Language Model and Truveta Data, the most complete and representative EHR data, Tru enables researchers to accelerate their research in Truveta Studio using simple, natural language BELLEVUE, Wash. – October 29, 2024 – Today, Truveta announced...
The CHOICE Institute partners with Truveta to advance health economics and outcomes research
Truveta will enable The CHOICE Institute with complete, timely, and clean real-world data to improve patient care and advance medicine The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy has...
Truveta’s real-world data study comparing tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss published in JAMA Internal Medicine
In the largest comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data – now published in JAMA Internal Medicine – Truveta Research found that patients with overweight or obesity taking tirzepatide were...
Truveta announces support for regulatory submissions to the FDA and global regulatory authorities
With industry-leading certifications and rigorous third-party audits, Truveta announces new capabilities to enable successful regulatory submissions and audits. BELLEVUE, Wash. – June 18, 2024 – Today, Truveta announced regulatory and audit capabilities to support its...
Truveta welcomes Rod Hochman, MD, president and CEO of Providence, as new Truveta Board of Directors Chair
BELLEVUE, Wash. – May 13, 2024 – Today Truveta, a growing collective of more than 30 health systems with a mission of Saving Lives with Data, welcomes Rod Hochman, MD, president and CEO of Providence, as its new Board of Directors Chair. Truveta’s Board of Directors...
Using clinical-led AI, Truveta expands clinical notes and medical images available to advance research
From detailed family history and complex concepts from a wide range of therapeutic areas to millions of de-identified medical images, Truveta empowers researchers with the most complete, timely, and clean data. BELLEVUE, Wash. – May 2, 2024 – Today Truveta announced...
